Abiopharma

General Announcement: Net Tangible Assets (NTA) Per Unit

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec un diabète de type 1 au stade 3

BORR Investors Have Opportunity to Join Borr Drilling Limited Fraud Investigation with the Schall Law Firm

UTHR: Notification

UTHR: Notification

BlackRock ESG Capital Allocation Term Trust (ECAT) Announces Certified Results of 2026 Annual Shareholder Meeting

Heartland Express, Inc. Declares Regular Quarterly Dividend

Gencor Releases Second Quarter Fiscal 2026 Results

Traws Pharma Provides Regulatory Update on Influenza Program